Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells

The emerging arthritogenic, mosquito-borne chikungunya virus (CHIKV) causes severe disease in humans and represents a serious public health threat in countries where Aedes spp mosquitoes are present. This study describes for the first time the successful production of CHIKV virus-like particles (VLPs) in insect cells using recombinant baculoviruses. This well-established expression system is rapidly scalable to volumes required for epidemic responses and proved well suited for processing of CHIKV glycoproteins and production of enveloped VLPs. Herein we show that a single immunization with 1 µg of non-adjuvanted CHIKV VLPs induced high titer neutralizing antibody responses and provided complete protection against viraemia and joint inflammation upon challenge with the Réunion Island CHIKV strain in an adult wild-type mouse model of CHIKV disease. CHIKV VLPs produced in insect cells using recombinant baculoviruses thus represents as a new, safe, non-replicating and effective vaccine candidate against CHIKV infections.

[1]  M. Rossmann,et al.  Structural Changes of Envelope Proteins During Alphavirus Fusion , 2010, Nature.

[2]  D. T. Brown,et al.  Assembly of the Sindbis virus spike protein complex. , 1996, Virology.

[3]  A. Suhrbier,et al.  A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. , 2011, Vaccine.

[4]  T. Scott,et al.  Consequences of the Expanding Global Distribution of Aedes albopictus for Dengue Virus Transmission , 2010, PLoS neglected tropical diseases.

[5]  G. Pijlman,et al.  Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. , 2011, Journal of invertebrate pathology.

[6]  Michele A. Kutzler,et al.  DNA vaccines: ready for prime time? , 2008, Nature Reviews Genetics.

[7]  J. Vlak,et al.  Development of a chitinase and v-cathepsin negative bacmid for improved integrity of secreted recombinant proteins. , 2004, Journal of virological methods.

[8]  C. Oker-Blom,et al.  Expression of Sindbis virus 26S cDNA in Spodoptera frugiperda (Sf9) cells, using a baculovirus expression vector , 1989, Journal of virology.

[9]  J. Vlak,et al.  Low Temperature-Dependent Salmonid Alphavirus Glycoprotein Processing and Recombinant Virus-Like Particle Formation , 2011, PloS one.

[10]  Thibaut Larcher,et al.  Chikungunya Virus Arthritis in Adult Wild-Type Mice , 2010, Journal of Virology.

[11]  N. Blom,et al.  Prediction of post‐translational glycosylation and phosphorylation of proteins from the amino acid sequence , 2004, Proteomics.

[12]  P. Roingeard,et al.  Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions , 2010, Journal of Virology.

[13]  G. Ludwig,et al.  Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. , 1999, Vaccine.

[14]  Mohsin Khan,et al.  Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. , 2009, Vaccine.

[15]  Volkman Le.  The 64K envelope protein of budded Autographa californica nuclear polyhedrosis virus. , 1986 .

[16]  M. V. van Oers.  Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors , 2006, Advances in Virus Research.

[17]  N. Sardesai,et al.  Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. , 2008, Vaccine.

[18]  Scott C Weaver,et al.  Chimeric alphavirus vaccine candidates for chikungunya. , 2008, Vaccine.

[19]  N. Seidah,et al.  Inhibition of Chikungunya Virus Infection in Cultured Human Muscle Cells by Furin Inhibitors , 2008, Journal of Biological Chemistry.

[20]  Manon M J Cox,et al.  FluBlok, a next generation influenza vaccine manufactured in insect cells. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[21]  C. Lindqvist,et al.  Synthesis and processing of the rubella virus p110 polyprotein precursor in baculovirus-infected Spodoptera frugiperda cells. , 1995, Virus research.

[22]  P. van Damme,et al.  Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial. , 2011, Vaccine.

[23]  D. O'reilly,et al.  Baculovirus expression vectors: a laboratory manual. , 1992 .

[24]  S. Higgs,et al.  A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection , 2010, Nature Medicine.

[25]  V. Arankalle,et al.  Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. , 2012, Vaccine.

[26]  Nicolas Gangneux,et al.  Prophylaxis and Therapy for Chikungunya Virus Infection , 2009, The Journal of infectious diseases.

[27]  P. Alves,et al.  Virus-like particles in vaccine development , 2010, Expert review of vaccines.

[28]  M. Borca,et al.  Effects of glycosylation on antigenicity and immunogenicity of classical swine fever virus envelope proteins. , 2011, Virology.

[29]  M. Betenbaugh,et al.  Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines , 2004, Glycoconjugate Journal.

[30]  L. Volkman.  The 64K envelope protein of budded Autographa californica nuclear polyhedrosis virus. , 1986, Current topics in microbiology and immunology.

[31]  M. Cox,et al.  A fast track influenza virus vaccine produced in insect cells. , 2011, Journal of invertebrate pathology.

[32]  R. Hopkins,et al.  A rapid method for titrating baculovirus stocks using the Sf-9 Easy Titer cell line. , 2009, BioTechniques.

[33]  Sun Park,et al.  Expression and Evaluation of Chikungunya Virus E1 and E2 Envelope Proteins for Serodiagnosis of Chikungunya Virus Infection , 2008, Yonsei medical journal.

[34]  M. V. van Oers.  Opportunities and challenges for the baculovirus expression system. , 2011, Journal of invertebrate pathology.

[35]  E. Wang,et al.  Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism , 2011, PLoS pathogens.

[36]  P. Repik,et al.  Development of an attenuated strain of chikungunya virus for use in vaccine production. , 1986, Vaccine.

[37]  S. Weaver,et al.  Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. , 2012, Vaccine.

[38]  M. Albert,et al.  Biology and pathogenesis of chikungunya virus , 2010, Nature Reviews Microbiology.

[39]  C. Tacket,et al.  Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. , 2000, The American journal of tropical medicine and hygiene.

[40]  M. Lehtinen,et al.  Introducing human papillomavirus vaccines—questions remain , 2008, Annals medicus.

[41]  M. Summers,et al.  A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures. , 1987 .

[42]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[43]  K. Morita,et al.  Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. , 2002, The Journal of general virology.

[44]  Shizuo Akira,et al.  Interferon Response Factors 3 and 7 Protect against Chikungunya Virus Hemorrhagic Fever and Shock , 2012, Journal of Virology.

[45]  P. Gasque,et al.  Arthritogenic alphaviruses—an overview , 2012, Nature Reviews Rheumatology.

[46]  J. Vlak,et al.  Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells , 2011, Virology Journal.

[47]  M. Ascher,et al.  Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). , 1979, The Journal of infectious diseases.

[48]  M. M. Oers,et al.  Vaccines for viral and parasitic diseases produced with baculovirus vectors. , 2006 .

[49]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[50]  M. Baker,et al.  4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus , 2011, The EMBO journal.

[51]  P. Bartelloni,et al.  Production and evaluation of a formalin-killed Chikungunya vaccine. , 1971, Journal of immunology.

[52]  N. Sardesai,et al.  A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates , 2011, PLoS neglected tropical diseases.

[53]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[54]  P. Alves,et al.  Large-scale production and purification of VLP-based vaccines , 2011, Journal of Invertebrate Pathology.